Please ensure Javascript is enabled for purposes of website accessibility

Why Rite Aid's Shares Crashed 19% in September

By Todd Campbell - Oct 5, 2017 at 7:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Changes that shrink its plan to sell stores to Walgreens, plus disappointing quarterly financials, weighed down the pharmacy retailer's stock last month.

What happened

Rite Aid (RAD -5.15%) and Walgreens Boots Alliance (WBA -2.92%) were forced by regulators to reduce the number of stores Rite Aid is selling to Walgreens and that news, plus Rite Aid's lackluster quarterly financial results, caused Rite Aid's shares to lose 19% of their value last month, according to S&P Global Market Intelligence.

So what

Rite Aid had been trying to cut a deal to sell itself lock, stock, and barrel to Walgreens. However, regulators balked at that proposal earlier this year, forcing the two companies to come up with a new plan. Instead, Walgreens agreed to acquire 2,186 Rite Aid stores and three distribution centers for $5.18 billion in cash.

A person bangs his fist on a desk while looking at a tablet displaying a declining stock price chart.


Unfortunately, that plan also failed to pass muster with regulators. In order to convince them to sign off on the deal, Walgreens had to reduce the number of stores it's acquiring to 1,932. As a result, Rite Aid will only collect $4.375 billion in cash. 

Rite Aid announced the restructured deal on Sept. 19, which coincides with a peak in Rite Aid's share price last month. However, that wasn't the only bad news that Rite Aid reported in September.

Management also rolled out quarterly results that were shy of what investors wanted to see. The company's revenue last quarter slipped 4.4% to $7.68 billion and after adjusting for one-time items, including a $325 million termination fee paid to it by Walgreens, lost $0.01 per share. 

Now what

Rite Aid blamed the anemic performance on the ongoing disruption caused by its M&A uncertainty. As a result, it filled fewer prescriptions, which caused foot traffic and front-end sales to decline. Overall, its same-store sales decreased 3.4% year over year.

It's been a horrible run for the embattled retail pharmacy chain, but perhaps there's hope for better times ahead. The company expects to finish transitioning stores to Walgreens early next year, and the cash influx from Walgreens will go a long way toward reducing its $7 billion in debt and $100 million per quarter in interest expense.

Easier comparisons next year, plus a renewed focus on kick-starting business that's inspired by new management, could position shares to trade higher. Of course, success depends largely on Rite Aid's execution of a strategy that regains consumer confidence and, arguably, Rite Aid's track record when it comes to executing isn't very good.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rite Aid Corporation Stock Quote
Rite Aid Corporation
$7.55 (-5.15%) $0.41
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$40.96 (-2.92%) $-1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.